Sulfonylurea Drug Class List

Drugs in Drug Class: Sulfonylurea

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-002	Jul 28, 2006	AB	RX	Yes	No			Y
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-001	Jul 28, 2006	AB	RX	Yes	Yes			Y
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-001	Jul 28, 2006	AB	RX	Yes	Yes			Y
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-002	Jul 28, 2006	AB	RX	Yes	No			Y

Sulfonylureas: Market Dynamics and Patent Landscape

Last updated: April 25, 2026

Sulfonylureas remain a core oral therapy class for type 2 diabetes, but the market has matured. Growth is driven mainly by line extensions (formulations, dosing convenience) and by competitive substitution around branded incumbents, while off-patent generics dominate volume. Patent value is concentrated in (1) specific branded products with later-life reforms (new dosage forms, improved release, new fixed-dose combinations) and (2) a small set of still-patented developers pursuing differentiated next-generation sulfonylureas rather than broad claims across the class.

---

How big is the sulfonylurea market, and what moves demand?

Sulfonylureas are established, low-cost oral glucose-lowering agents. They face persistent competitive pressure from newer drug classes (GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors), but remain widely used due to low price and long clinical familiarity.

Demand drivers

• Price and reimbursement: Generic sulfonylureas anchor most formularies where budget control matters.
• Clinical positioning: Sulfonylureas are used for added glycemic lowering when inexpensive oral options are needed.
• Titration and adherence: Once-daily or simplified regimens in branded lines can retain incremental share even as generics expand.
• Safety perception: Hypoglycemia risk shapes clinician and payer comfort, which can shift prescribing away from sulfonylureas versus newer classes.

Competitive dynamics

• Generic erosion: Most legacy sulfonylureas are off-patent, leading to heavy price compression and margin pressure.
• Switching costs are low: Molecule substitution within the class is common when efficacy expectations are aligned.
• Differentiation is formulation-driven: When brands retain value, it is often because they control a specific dosage form or combination product rather than the active ingredient alone.

---

Which sulfonylureas dominate commercially today?

The class centers on second-generation agents for potency and longer duration. Market share is typically split among a small set of widely used molecules plus legacy brands, with generics taking large volume.

Key sulfonylureas (commercially entrenched)

• Glibenclamide (glyburide)
• Gliclazide
• Glimepiride
• Tolbutamide (more legacy in many markets)
• Glipizide (not always first-line but widely available)

Where branded value still shows

• Products that maintain exclusivity through specific presentations, extended release, or fixed-dose combinations tend to sustain a pricing premium longer than products whose exclusivity ends at API patent expiry.

---

What is the patent landscape like for sulfonylureas?

The sulfonylurea patent landscape is characterized by:

1. Early core API patents that mostly expired for major molecules.
2. Later-life patents that cluster around:
   • new crystalline forms/polymorphs,
   • improved manufacturing processes,
   • new strengths and dosing regimens,
   • modified-release tablets,
   • combinations (with metformin or other diabetes agents),
   • use-related claims (less common to remain broad given established clinical use).
3. Generic entry readiness driven by well-established formulation pathways and bioequivalence standards.

Practical implication
For investors and R&D teams, the viable patent targets tend to be narrower and product-specific rather than “class-covering” claims. Case-by-case claim survival is decisive because generic challenge strategies focus on design-around and invalidity leverage based on prior art in pharmaceutical salts, polymorphs, and process disclosures.

---

What patent “buckets” create remaining exclusivity risk or opportunity?

1) API patents (rarely the value center now)

Core patents on established sulfonylureas are largely expired in most major jurisdictions. Remaining exclusivity, where present, typically comes from non-API layers.

2) Polymorphs, solvates, and crystal forms

• Claim sets typically cover specific solid-state forms with distinct characterization.
• Commercial relevance depends on whether the marketed product uses the claimed form or a close variant.

3) Modified-release and dosing forms

• Extended release or altered pharmacokinetic profiles can support patents on:
  • formulation composition,
  • excipient systems,
  • manufacturing method,
  • performance targets (release profile).
• These patents are often more defensible than broad “use” claims because they map to manufacturing and product structure.

4) Fixed-dose combinations

• Combination products are a frequent exclusivity pocket:
  • branded fixed-dose pill,
  • titratable pack strategy,
  • separate patents for each component combination and dosing.

5) Regulatory exclusivities and pediatric add-ons (market impact lever)

• In some cases, regulatory pathways can extend marketing protection at the product level even after active ingredient patents expire, depending on jurisdiction and submissions.

---

How do generics attack sulfonylurea patents in practice?

Generic entrants typically use a three-part playbook:

• ANDA-style bioequivalence strategy where applicable (for the US).
• Non-infringement via different crystal form, different excipient system, or different release profile.
• Invalidity arguments rooted in prior art:
  • earlier patents and publications on polymorphs and processes,
  • conventional formulation know-how,
  • predictable release mechanisms.

Because sulfonylureas have long histories, prior art density is high. This increases the importance of narrow, product-linked claims.

---

What does the competitive patent strategy look like across the class?

The patent strategy often converges on similar themes because the science is mature:

• Branded manufacturers prioritize:
  • line extensions with demonstrable performance improvements,
  • solid-state differentiation,
  • combination products that lock into formulary pathways.
• Generic manufacturers prioritize:
  • design-around within excipients and solid-state,
  • rapid entry post-expiry,
  • challenging remaining patents that are perceived as weakly novel.

---

Are there any still-material “next-generation” sulfonylurea platforms?

For business decisions, the key question is whether a developer’s sulfonylurea program controls:

• a new molecular scaffold with meaningful non-class pharmacology (rare for this mature class), or
• a clearly defensible and manufacturable formulation platform with broad claim coverage (still uncommon).

Most activity seen in mature sulfonylureas is incremental. The risk is that a “next-generation” claim set collapses under prior-art scrutiny if it does not clearly anchor to a distinct chemical form or an engineered performance target.

---

What market protections exist beyond patents?

Patents are necessary but not sufficient for sustained share. For sulfonylureas, additional practical protections include:

• Formulary positioning: established branded familiarity can delay substitution.
• Pack sizes and dosing convenience: lower friction in procurement and switching.
• Physician inertia: some prescribers keep stable therapy unless a clear safety/efficacy issue arises.

These levers often outlast patent exclusivity in specific contracts, though they do not stop generic price undercutting.

---

How should R&D and investment teams screen sulfonylurea opportunities?

High-probability patent value checks

• The product must map to a distinct, claimed solid-state form used in commercial manufacturing.
• The formulation should have measurable performance differentiation (release profile, stability, bioavailability) that is tightly linked to claim elements.
• The patent should be jurisdiction-aware:
  • claims that survive in one system may not survive in another due to different standards of novelty, inventive step, and claim construction.

Low-probability patent value checks

• Broad method-of-use claims that track known clinical practice without a clear novelty axis.
• “Generically described” formulations where the claim elements are not tightly tied to the marketed product’s composition or manufacturing steps.

---

Key Takeaways

• Sulfonylureas are a mature, price-sensitive diabetes class where demand growth is modest and share shifts are mostly competitive.
• Patent value is concentrated in product-specific exclusivity layers, especially modified-release/formulation and solid-state claims, not in core API patents.
• Generic pressure is durable; sustained share premiums depend on narrow claim defensibility and real-world product differentiation that is hard to design around.
• The most investable sulfonylurea opportunities are those where exclusivity is tied to a manufacturable, marketed differentiator rather than broad class-level claims.

---

FAQs

1) What is the main driver of post-patent erosion in sulfonylureas?

Generic substitution enabled by mature manufacturing know-how, dense prior art, and bioequivalence-based regulatory pathways.

2) Where do patents tend to survive the longest in sulfonylureas?

Later-life product patents that cover specific formulations, modified release, and solid-state forms used in the marketed product.

3) Do “new indications” patents materially change the sulfonylurea landscape?

Usually not unless the indication is both clinically differentiated and supported by a narrow, technically anchored claim set.

4) Why do fixed-dose combinations matter for sulfonylurea exclusivity?

Combinations can create additional regulatory and product-level differentiation that supports separate exclusivity and can slow switching due to pack and dosing convenience.

5) What is the biggest strategic risk when entering sulfonylurea development?

Overestimating broad “class” patent coverage when real remaining value is narrow and product-specific.

---

References

[1] International Diabetes Federation. Diabetes Atlas (latest edition available at time of access). International Diabetes Federation.
[2] U.S. Food and Drug Administration. Abbreviated New Drug Application (ANDA) regulatory framework and bioequivalence principles. FDA.
[3] European Medicines Agency. Guideline on the investigation of bioequivalence. EMA.
[4] World Health Organization. Definition and diagnosis of diabetes mellitus and classification of glycemic disorders (diabetes foundational guidance). WHO.
[5] U.S. National Library of Medicine. PubChem and pharmacology entries for sulfonylureas (active ingredient reference points).